Wilson Martin 4
4 · ROCKET PHARMACEUTICALS, INC. · Filed May 20, 2024
Insider Transaction Report
Form 4
Wilson Martin
General Counsel
Transactions
- Other
Restricted Stock Units
2022-08-12−28,763→ 0 total→ Common Stock (28,763 underlying) - Exercise/Conversion
Common Stock
2024-05-14+2,420→ 21,100 total - Other
Common Stock
2023-02-14+16,947→ 66,810 total - Sale
Common Stock
2024-05-16$23.35/sh−1,048$24,471→ 65,762 total - Exercise/Conversion
Restricted Stock Units
2024-05-14−2,420→ 16,947 total→ Common Stock (2,420 underlying) - Other
Restricted Stock Units
2023-02-14−16,947→ 0 total→ Common Stock (16,947 underlying) - Other
Common Stock
2022-08-12+28,763→ 49,863 total
Footnotes (5)
- [F1]Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.
- [F2]Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.
- [F3]Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025.
- [F4]The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
- [F5]Each RSU represents a contingent right to receive one share of the Issuer's common stock.